Advertisement

Head and Neck Pathology

, Volume 11, Issue 3, pp 314–320 | Cite as

Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck

  • Julia Thierauf
  • Johannes A. Veit
  • Jochen K. Lennerz
  • Stephanie E. Weissinger
  • Annette Affolter
  • Johannes Döscher
  • Christoph Bergmann
  • Andreas Knopf
  • Jennifer Grünow
  • Lisa Grünmüller
  • Cornelia Mauch
  • Peter K. Plinkert
  • Thomas K. Hoffmann
  • Jochen Hess
Original Paper

Abstract

Mucosal melanomas of the head and neck (MMHN) are aggressive tumors with poor prognosis, different opposed to cutaneous melanoma. In this study, we characterized primary mucosal malignant melanoma for the expression of Kallikrein-related peptidase 6 (KLK6), a member of the KLK family with relevance to the malignant phenotype in various cancer types including cutaneous melanoma. Paraffin-embedded MMHN of 22 patients were stained immunohistochemically for KLK6 and results were correlated with clinical and pathological data. In 77.3% (17/22) of MMHN cases, positive KLK6 staining was found. Staining pattern for tumor cells showed a predominant cytoplasmic staining. However, in six cases we also observed a prominent nuclear staining. MMHN with a high KLK6 expression showed significantly better outcome concerning local recurrence-free survival (p = 0.013) and nuclear KLK6 staining was significantly associated with the survival status (p = 0.027). Overexpression of KLK6 was detected in more than 70% of MMHN and approximately 40% of tumors showed a strong expression pattern. Correlation between clinical outcome of MMHN patients and overexpression of KLK6 has not been addressed so far. Our data demonstrate for the first time increased levels of KLK6 in MMHN and strengthen the hypothesis that there might be a context-specific regulation and function of KLK6 in mucosal melanoma.

Keywords

Mucosal melanoma Head and neck cancer Kallikrein-related peptidase 6 KLK6 

References

  1. 1.
    Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol. 2012;5:739–53.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Prasad ML, et al. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck. 2004;26:1053–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Holmstrom M, Lund VJ. Malignant melanomas of the nasal cavity after occupational exposure to formaldehyde. Br J Ind Med. 1991;48:9–11.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Dahlgren L, Schedvins K, Kanter-Lewensohn L, Dalianis T, Ragnarsson-Olding BK. Human papilloma virus (HPV) is rarely detected in malignant melanomas of sun sheltered mucosal membranes. Acta Oncol. 2005;44:694–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Lundberg R, et al. Human herpes virus DNA is rarely detected in non-UV light-associated primary malignant melanomas of mucous membranes. Anticancer Res. 2006;26:3627–31.PubMedGoogle Scholar
  6. 6.
    Thierauf J, et al. Mucosal melanoma of the head and neck. Laryngorhinootologie. 2015;94:812–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Liao JJ, et al. Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. Head Neck. 2013. doi: 10.1002/hed.23428.Google Scholar
  8. 8.
    Zenda S, et al. Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. Int J Radiat Oncol Biol Phys. 2011;81:135–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Yi JH, et al. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011;21:223–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Hodi FS, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Minor DR, et al. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012;18:1457–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Lourenço SV, et al. Head and neck mucosal melanoma: a review. Am J Dermatopathol. 2014. doi: 10.1097/DAD.0000000000000035.Google Scholar
  13. 13.
    Thierauf J, et al. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res. 2015. doi: 10.1097/CMR.0000000000000197.PubMedGoogle Scholar
  14. 14.
    Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007;249:61–79.CrossRefPubMedGoogle Scholar
  15. 15.
    Yousef GM, et al. Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem. 2005;39:11–79.CrossRefPubMedGoogle Scholar
  16. 16.
    Prassas I, Eissa A, Poda G, Diamandis EP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov. 2015;14:183–202.CrossRefPubMedGoogle Scholar
  17. 17.
    Bayani J, Diamandis EP. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med. 2012;50:211–33.CrossRefGoogle Scholar
  18. 18.
    Krenzer S, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Investig Dermatol. 2011;131:2281–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Oikonomopoulou K, Diamandis EP, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol Chem. 2010;391:299–310.PubMedGoogle Scholar
  20. 20.
    Drucker KL, et al. Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro Oncol. 2013;15:305–18.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pampalakis G, et al. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 2009;69:3779–87.CrossRefPubMedGoogle Scholar
  22. 22.
    Schrader CH, et al. Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Mol Cancer. 2015;14:107.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Paliouras M, Diamandis EP. Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor. Mol Oncol. 2008;1:413–24.CrossRefPubMedGoogle Scholar
  24. 24.
    Breitenbach U, et al. Keratinocyte-specific onset of serine protease BSSP expression in experimental carcinogenesis. J Investig Dermatol. 2001;117:634–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Ignatenko NA, et al. The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells. Mol Carcinog. 2004;39:221–33.CrossRefPubMedGoogle Scholar
  26. 26.
    Kuzmanov U, et al. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics. 2012;12:799–809.CrossRefPubMedGoogle Scholar
  27. 27.
    Chow TF, et al. Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol Chem. 2008;389:731–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Klucky B, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 2007;67:8198–206.CrossRefPubMedGoogle Scholar
  29. 29.
    van Diest PJ, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol. 1997;50:801–4.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Qureshi A, Pervez S. Allred scoring for ER reporting and it’s impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc. 2010;60:350–3.PubMedGoogle Scholar
  31. 31.
    Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996;2:624–36.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Seiz L, et al. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem. 2012;393:391–401.CrossRefPubMedGoogle Scholar
  33. 33.
    Gabril M, et al. Immunohistochemical analysis of kallikrein-related peptidases in the normal kidney and renal tumors: potential clinical implications. Biol Chem. 2010;391:403–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Julia Thierauf
    • 1
  • Johannes A. Veit
    • 1
  • Jochen K. Lennerz
    • 4
    • 5
  • Stephanie E. Weissinger
    • 4
  • Annette Affolter
    • 2
    • 6
  • Johannes Döscher
    • 1
  • Christoph Bergmann
    • 8
  • Andreas Knopf
    • 9
  • Jennifer Grünow
    • 2
  • Lisa Grünmüller
    • 4
  • Cornelia Mauch
    • 7
  • Peter K. Plinkert
    • 2
  • Thomas K. Hoffmann
    • 1
  • Jochen Hess
    • 2
    • 3
  1. 1.Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Medical Center UlmUlmGermany
  2. 2.Section Experimental and Translational Head and Neck Oncology, Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Medical Center HeidelbergHeidelbergGermany
  3. 3.Research Group Molecular Mechanisms of Head and Neck TumorsGerman Cancer Research Center (DKFZ)HeidelbergGermany
  4. 4.Institute of PathologyUniversity Medical Center UlmUlmGermany
  5. 5.Department of PathologyMassachusetts General HospitalBostonUSA
  6. 6.Institute of PathologyUniversity Medical Center HeidelbergHeidelbergGermany
  7. 7.Department of Dermatology and VenerologyUniversity Medical Center of CologneCologneGermany
  8. 8.Department of Otorhinolaryngology, Head and Neck SurgeryUniversity Medical Center EssenEssenGermany
  9. 9.Department of Otolaryngology, Head and Neck SurgeryTechnical University Hospital MunichMunichGermany

Personalised recommendations